ASTRANA HEALTH INC (ASTH) Fundamental Analysis & Valuation

NASDAQ:ASTH • US03763A2078

23.25 USD
-0.94 (-3.89%)
At close: Mar 12, 2026
23.25 USD
0 (0%)
After Hours: 3/12/2026, 8:23:47 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ASTH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, ASTH scores 3 out of 10 in our fundamental rating. ASTH was compared to 101 industry peers in the Health Care Providers & Services industry. ASTH has a medium profitability rating, but doesn't score so well on its financial health evaluation. ASTH has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. ASTH Profitability Analysis

1.1 Basic Checks

  • ASTH had positive earnings in the past year.
  • ASTH had a positive operating cash flow in the past year.
  • Of the past 5 years ASTH 4 years were profitable.
  • Of the past 5 years ASTH 4 years had a positive operating cash flow.
ASTH Yearly Net Income VS EBIT VS OCF VS FCFASTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

  • ASTH has a Return On Assets (0.43%) which is in line with its industry peers.
  • ASTH has a Return On Equity (1.23%) which is comparable to the rest of the industry.
  • The Return On Invested Capital of ASTH (2.95%) is comparable to the rest of the industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for ASTH is in line with the industry average of 8.98%.
  • The 3 year average ROIC (7.07%) for ASTH is well above the current ROIC(2.95%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 0.43%
ROE 1.23%
ROIC 2.95%
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ASTH Yearly ROA, ROE, ROICASTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • ASTH has a Profit Margin (0.33%) which is comparable to the rest of the industry.
  • ASTH's Profit Margin has declined in the last couple of years.
  • ASTH has a Operating Margin of 2.59%. This is comparable to the rest of the industry: ASTH outperforms 51.49% of its industry peers.
  • In the last couple of years the Operating Margin of ASTH has declined.
  • Looking at the Gross Margin, with a value of 10.25%, ASTH is doing worse than 73.27% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ASTH has declined.
Industry RankSector Rank
OM 2.59%
PM (TTM) 0.33%
GM 10.25%
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
ASTH Yearly Profit, Operating, Gross MarginsASTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ASTH Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ASTH is destroying value.
  • There is no outstanding debt for ASTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ASTH Yearly Shares OutstandingASTH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
ASTH Yearly Total Debt VS Total AssetsASTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • ASTH has an Altman-Z score of 2.21. This is not the best score and indicates that ASTH is in the grey zone with still only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.21, ASTH is in line with its industry, outperforming 53.47% of the companies in the same industry.
  • ASTH has a debt to FCF ratio of 10.83. This is a negative value and a sign of low solvency as ASTH would need 10.83 years to pay back of all of its debts.
  • ASTH has a Debt to FCF ratio of 10.83. This is comparable to the rest of the industry: ASTH outperforms 43.56% of its industry peers.
  • ASTH has a Debt/Equity ratio of 1.29. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 1.29, ASTH is not doing good in the industry: 65.35% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF 10.83
Altman-Z 2.21
ROIC/WACC0.36
WACC8.19%
ASTH Yearly LT Debt VS Equity VS FCFASTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 1.40 indicates that ASTH should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.40, ASTH perfoms like the industry average, outperforming 53.47% of the companies in the same industry.
  • A Quick Ratio of 1.40 indicates that ASTH should not have too much problems paying its short term obligations.
  • The Quick ratio of ASTH (1.40) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
ASTH Yearly Current Assets VS Current LiabilitesASTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ASTH Growth Analysis

3.1 Past

  • The earnings per share for ASTH have decreased strongly by -48.31% in the last year.
  • Measured over the past years, ASTH shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.29% on average per year.
EPS 1Y (TTM)-48.31%
EPS 3Y-24.29%
EPS 5YN/A
EPS Q2Q%180%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%42.89%

3.2 Future

  • The Earnings Per Share is expected to grow by 54.34% on average over the next years. This is a very strong growth
  • ASTH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.59% yearly.
EPS Next Y174.35%
EPS Next 2Y103.85%
EPS Next 3Y87.86%
EPS Next 5Y54.34%
Revenue Next Year25.22%
Revenue Next 2Y17.78%
Revenue Next 3Y10.21%
Revenue Next 5Y9.59%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
ASTH Yearly Revenue VS EstimatesASTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
ASTH Yearly EPS VS EstimatesASTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

5

4. ASTH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 50.54, which means the current valuation is very expensive for ASTH.
  • ASTH's Price/Earnings ratio is in line with the industry average.
  • The average S&P500 Price/Earnings ratio is at 25.71. ASTH is valued rather expensively when compared to this.
  • ASTH is valuated rather expensively with a Price/Forward Earnings ratio of 18.42.
  • ASTH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ASTH is cheaper than 63.37% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.82. ASTH is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 50.54
Fwd PE 18.42
ASTH Price Earnings VS Forward Price EarningsASTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • ASTH's Enterprise Value to EBITDA is on the same level as the industry average.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ASTH indicates a somewhat cheap valuation: ASTH is cheaper than 79.21% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 12.03
EV/EBITDA 15.55
ASTH Per share dataASTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

  • ASTH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ASTH's earnings are expected to grow with 87.86% in the coming years.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y103.85%
EPS Next 3Y87.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ASTH Dividend Analysis

5.1 Amount

  • No dividends for ASTH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASTH Fundamentals: All Metrics, Ratios and Statistics

ASTRANA HEALTH INC

NASDAQ:ASTH (3/12/2026, 8:23:47 PM)

After market: 23.25 0 (0%)

23.25

-0.94 (-3.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-02
Earnings (Next)05-06
Inst Owners59.72%
Inst Owner ChangeN/A
Ins Owners9.87%
Ins Owner Change0.85%
Market Cap1.17B
Revenue(TTM)N/A
Net Income(TTM)9.54M
Analysts84.71
Price Target36.38 (56.47%)
Short Float %7.27%
Short Ratio4.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP86.52%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73.24%
Min EPS beat(2)-97.78%
Max EPS beat(2)-48.7%
EPS beat(4)0
Avg EPS beat(4)-104%
Min EPS beat(4)-225.16%
Max EPS beat(4)-44.39%
EPS beat(8)4
Avg EPS beat(8)-42.64%
EPS beat(12)7
Avg EPS beat(12)-21.5%
EPS beat(16)10
Avg EPS beat(16)-9.93%
Revenue beat(2)1
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-1.62%
Max Revenue beat(2)0.57%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)5.66%
Revenue beat(8)5
Avg Revenue beat(8)0.99%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.13%
PT rev (3m)-11.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-30.36%
EPS NY rev (1m)-0.18%
EPS NY rev (3m)-16.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
Industry RankSector Rank
PE 50.54
Fwd PE 18.42
P/S 0.4
P/FCF 12.03
P/OCF 10.95
P/B 1.5
P/tB N/A
EV/EBITDA 15.55
EPS(TTM)0.46
EY1.98%
EPS(NY)1.26
Fwd EY5.43%
FCF(TTM)1.93
FCFY8.31%
OCF(TTM)2.12
OCFY9.14%
SpS57.74
BVpS15.46
TBVpS-7.43
PEG (NY)0.29
PEG (5Y)N/A
Graham Number12.65
Profitability
Industry RankSector Rank
ROA 0.43%
ROE 1.23%
ROCE 4.68%
ROIC 2.95%
ROICexc 4.15%
ROICexgc N/A
OM 2.59%
PM (TTM) 0.33%
GM 10.25%
FCFM 3.35%
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexgc growth 3Y-13.47%
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score3
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF 10.83
Debt/EBITDA 8.9
Cap/Depr 25.55%
Cap/Sales 0.33%
Interest Coverage 2.01
Cash Conversion 94.59%
Profit Quality 1016.69%
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z 2.21
F-Score3
WACC8.19%
ROIC/WACC0.36
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-48.31%
EPS 3Y-24.29%
EPS 5YN/A
EPS Q2Q%180%
EPS Next Y174.35%
EPS Next 2Y103.85%
EPS Next 3Y87.86%
EPS Next 5Y54.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%42.89%
Revenue Next Year25.22%
Revenue Next 2Y17.78%
Revenue Next 3Y10.21%
Revenue Next 5Y9.59%
EBIT growth 1Y-11.33%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year101.88%
EBIT Next 3Y45.21%
EBIT Next 5Y30.45%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A

ASTRANA HEALTH INC / ASTH FAQ

Can you provide the ChartMill fundamental rating for ASTRANA HEALTH INC?

ChartMill assigns a fundamental rating of 3 / 10 to ASTH.


What is the valuation status of ASTRANA HEALTH INC (ASTH) stock?

ChartMill assigns a valuation rating of 4 / 10 to ASTRANA HEALTH INC (ASTH). This can be considered as Fairly Valued.


How profitable is ASTRANA HEALTH INC (ASTH) stock?

ASTRANA HEALTH INC (ASTH) has a profitability rating of 4 / 10.


What is the valuation of ASTRANA HEALTH INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ASTRANA HEALTH INC (ASTH) is 50.54 and the Price/Book (PB) ratio is 1.5.


Can you provide the financial health for ASTH stock?

The financial health rating of ASTRANA HEALTH INC (ASTH) is 3 / 10.